Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Drug: Placebo

First Posted Date: 2011-11-18

Last Posted Date: 2019-10-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1296

Registration Number: NCT01474512

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lanarkshire, United Kingdom

Effect of Teriparatide on Hip Fracture Healing

Phase 3

Completed

Conditions: Femur Neck Fracture

Interventions: Drug: Placebo
Drug: Teriparatide
Dietary Supplement: Calcium supplementation
Dietary Supplement: Vitamin D supplementation

First Posted Date: 2011-11-17

Last Posted Date: 2015-04-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 122

Registration Number: NCT01473589

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

Second Study of the Effect of Teriparatide on Hip Fracture Healing

Phase 3

Completed

Conditions: Femur Neck Fracture

Interventions: Drug: Placebo
Drug: Teriparatide
Dietary Supplement: Calcium supplementation
Dietary Supplement: Vitamin D supplementation

First Posted Date: 2011-11-17

Last Posted Date: 2015-04-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT01473602

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey

A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Nonsquamous Non-Small Cell Neoplasm of Lung
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer Stage IIIB

Interventions: Drug: Pemetrexed

First Posted Date: 2011-11-17

Last Posted Date: 2014-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT01473563

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: Methotrexate
Drug: Baricitinib

First Posted Date: 2011-11-10

Last Posted Date: 2019-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 145

Registration Number: NCT01469013

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toyama, Japan

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Drug: Gefitinib
Drug: Pemetrexed

First Posted Date: 2011-11-10

Last Posted Date: 2019-09-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 195

Registration Number: NCT01469000

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

A Study in Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2605541
Drug: Insulin Glargine
Drug: Insulin Lispro

First Posted Date: 2011-11-10

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1369

Registration Number: NCT01468987

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LY2189265
Drug: Thiazolidinedione (TZD)
Drug: alpha-glucosidase inhibitor (a-GI)
Drug: Glinides
Drug: Biguanides (BG)
Drug: Sulfonylureas (SU)

First Posted Date: 2011-11-09

Last Posted Date: 2015-01-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 394

Registration Number: NCT01468181

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wakayama, Japan

A Study of LY3007113 in Participants With Advanced Cancer

Phase 1

Completed

Conditions: Metastatic Cancer

Interventions: Drug: LY3007113

First Posted Date: 2011-11-02

Last Posted Date: 2018-08-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT01463631

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil

First Posted Date: 2011-10-26

Last Posted Date: 2013-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 610

Registration Number: NCT01460342

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy